The combination will create a leading women’s health and dermatology focused pharmaceuticals company in the U.S. with an established presence in international markets…
The nominal deal value is USD430M.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”